These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 29991680)

  • 1. Patterns of genomic evolution in advanced melanoma.
    Birkeland E; Zhang S; Poduval D; Geisler J; Nakken S; Vodak D; Meza-Zepeda LA; Hovig E; Myklebost O; Knappskog S; Lønning PE
    Nat Commun; 2018 Jul; 9(1):2665. PubMed ID: 29991680
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dynamic Evolution of Clonal Composition and Neoantigen Landscape in Recurrent Metastatic Melanoma with a Rare Combination of Driver Mutations.
    Davidson G; Coassolo S; Kieny A; Ennen M; Pencreach E; Malouf GG; Lipsker D; Davidson I
    J Invest Dermatol; 2019 Aug; 139(8):1769-1778.e2. PubMed ID: 30776432
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early contribution of germline and nevi genetic alterations to a rapidly-progressing cutaneous melanoma patient: a case report.
    Mordoh A; Triviño Pardo JC; Carri I; Barrio MM; Mordoh J; Aris M
    BMC Med Genomics; 2023 Jan; 16(1):1. PubMed ID: 36604730
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clonal architectures and driver mutations in metastatic melanomas.
    Ding L; Kim M; Kanchi KL; Dees ND; Lu C; Griffith M; Fenstermacher D; Sung H; Miller CA; Goetz B; Wendl MC; Griffith O; Cornelius LA; Linette GP; McMichael JF; Sondak VK; Fields RC; Ley TJ; Mulé JJ; Wilson RK; Weber JS
    PLoS One; 2014; 9(11):e111153. PubMed ID: 25393105
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comprehensive genomic analysis of primary malignant melanoma of the esophagus reveals similar genetic patterns compared with epithelium-associated melanomas.
    Li J; Liu B; Ye Q; Xiao X; Yan S; Guan W; He L; Wang C; Yu Z; Tai Z; Pei S; Ma Y; Li S; Wang Y; Wu N
    Mod Pathol; 2022 Nov; 35(11):1596-1608. PubMed ID: 35688970
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative study on driver mutations in primary and metastatic melanomas at a single Japanese institute: A clue for intra- and inter-tumor heterogeneity.
    Kaji T; Yamasaki O; Takata M; Otsuka M; Hamada T; Morizane S; Asagoe K; Yanai H; Hirai Y; Umemura H; Iwatsuki K
    J Dermatol Sci; 2017 Jan; 85(1):51-57. PubMed ID: 27771229
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular and genetic diversity in the metastatic process of melanoma.
    Harbst K; Lauss M; Cirenajwis H; Winter C; Howlin J; Törngren T; Kvist A; Nodin B; Olsson E; Häkkinen J; Jirström K; Staaf J; Lundgren L; Olsson H; Ingvar C; Gruvberger-Saal SK; Saal LH; Jönsson G
    J Pathol; 2014 May; 233(1):39-50. PubMed ID: 24399611
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Allele frequencies of BRAFV600 mutations in primary melanomas and matched metastases and their relevance for BRAF inhibitor therapy in metastatic melanoma.
    Satzger I; Marks L; Kerick M; Klages S; Berking C; Herbst R; Völker B; Schacht V; Timmermann B; Gutzmer R
    Oncotarget; 2015 Nov; 6(35):37895-905. PubMed ID: 26498143
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment of clinical parameters associated with mutational status in metastatic malignant melanoma: a single-centre investigation of 141 patients.
    Schlaak M; Bajah A; Podewski T; Kreuzberg N; von Bartenwerffer W; Wardelmann E; Merkelbach-Bruse S; Büttner R; Mauch C; Kurschat P
    Br J Dermatol; 2013 Apr; 168(4):708-16. PubMed ID: 23528057
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BRAF/NRAS mutation frequencies among primary tumors and metastases in patients with melanoma.
    Colombino M; Capone M; Lissia A; Cossu A; Rubino C; De Giorgi V; Massi D; Fonsatti E; Staibano S; Nappi O; Pagani E; Casula M; Manca A; Sini M; Franco R; Botti G; Caracò C; Mozzillo N; Ascierto PA; Palmieri G
    J Clin Oncol; 2012 Jul; 30(20):2522-9. PubMed ID: 22614978
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BRAF mutation status is an independent prognostic factor for resected stage IIIB and IIIC melanoma: implications for melanoma staging and adjuvant therapy.
    Barbour AP; Tang YH; Armour N; Dutton-Regester K; Krause L; Loffler KA; Lambie D; Burmeister B; Thomas J; Smithers BM; Hayward NK
    Eur J Cancer; 2014 Oct; 50(15):2668-76. PubMed ID: 25070294
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evolution of late-stage metastatic melanoma is dominated by aneuploidy and whole genome doubling.
    Vergara IA; Mintoff CP; Sandhu S; McIntosh L; Young RJ; Wong SQ; Colebatch A; Cameron DL; Kwon JL; Wolfe R; Peng A; Ellul J; Dou X; Fedele C; Boyle S; Arnau GM; Raleigh J; Hatzimihalis A; Szeto P; Mooi J; Widmer DS; Cheng PF; Amann V; Dummer R; Hayward N; Wilmott J; Scolyer RA; Cho RJ; Bowtell D; Thorne H; Alsop K; Cordner S; Woodford N; Leditschke J; O'Brien P; Dawson SJ; McArthur GA; Mann GJ; Levesque MP; Papenfuss AT; Shackleton M
    Nat Commun; 2021 Mar; 12(1):1434. PubMed ID: 33664264
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BRAF mutation-positive folliculotropic metastatic melanoma.
    Brick KE; Halling KC; Khan YK; Peters MS
    Am J Dermatopathol; 2013 Jul; 35(5):609-12. PubMed ID: 23715079
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intra-patient Heterogeneity of BRAF and NRAS Molecular Alterations in Primary Melanoma and Metastases.
    Pellegrini C; Cardelli L; Padova M; Nardo LD; Ciciarelli V; Rocco T; Cipolloni G; Clementi M; Cortellini A; Ventura A; Leocata P; Fargnoli MC
    Acta Derm Venereol; 2020 Jan; 100(1):adv00040. PubMed ID: 31774543
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mutation landscape in melanoma patients clinical implications of heterogeneity of BRAF mutations.
    Heinzerling L; Baiter M; Kühnapfel S; Schuler G; Keikavoussi P; Agaimy A; Kiesewetter F; Hartmann A; Schneider-Stock R
    Br J Cancer; 2013 Nov; 109(11):2833-41. PubMed ID: 24196789
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Characterization of genetic alterations in primary human melanomas carrying BRAF or NRAS mutation].
    Lázár V
    Magy Onkol; 2013 Jun; 57(2):96-9. PubMed ID: 23795354
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comprehensive genomic characterization of cutaneous malignant melanoma cell lines derived from metastatic lesions by whole-exome sequencing and SNP array profiling.
    Cifola I; Pietrelli A; Consolandi C; Severgnini M; Mangano E; Russo V; De Bellis G; Battaglia C
    PLoS One; 2013; 8(5):e63597. PubMed ID: 23704925
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stability of BRAF V600E mutation in metastatic melanoma: new insights for therapeutic success?
    Sigalotti L; Fratta E; Parisi G; Coral S; Maio M
    Br J Cancer; 2011 Jul; 105(2):327-8. PubMed ID: 21694724
    [No Abstract]   [Full Text] [Related]  

  • 19. Marked genetic differences between BRAF and NRAS mutated primary melanomas as revealed by array comparative genomic hybridization.
    Lázár V; Ecsedi S; Vízkeleti L; Rákosy Z; Boross G; Szappanos B; Bégány A; Emri G; Adány R; Balázs M
    Melanoma Res; 2012 Jun; 22(3):202-14. PubMed ID: 22456166
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAF
    Dummer R; Brase JC; Garrett J; Campbell CD; Gasal E; Squires M; Gusenleitner D; Santinami M; Atkinson V; Mandalà M; Chiarion-Sileni V; Flaherty K; Larkin J; Robert C; Kefford R; Kirkwood JM; Hauschild A; Schadendorf D; Long GV
    Lancet Oncol; 2020 Mar; 21(3):358-372. PubMed ID: 32007138
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.